Pfizer suspends sale & use of some in style merchandise in India because of technical points – ET HealthWorld

0
4
Pfizer suspends sale & use of some in style merchandise in India because of technical points – ET HealthWorld


New Delhi: Pfizer Ltd, the Indian unit of US drug maker Pfizer Inc has suspended sale and use of its in style merchandise used for bacterial infections in India on account of sure technical points confronted by the contract manufacturing website.

In a letter written to stockists, distributors and hospitals throughout India, Pfizer has requested for momentary suspension of sale and distribution of Magzex, Zosyn, Magnamycin injections and Magnex forte provides with speedy impact.

The transfer follows an info from the Vadodara based mostly producer -Astral Steritech Personal Restricted, which informed Pfizer of sure deviations noticed at their manufacturing facility when the merchandise had been manufactured.

It mentioned that the producer is at present investigating the matter. “They’ve requested Pfizer as an plentiful precautionary measure and as per the most effective practices to briefly droop the sale, distribution and provide and use of the merchandise, pending the investigation by the producer,” it has mentioned in its letter.

It has requested the stockists to not undertake any additional sale, distribution or use of the merchandise until additional discover from Pfizer. Pfizer is taking “all affordable efforts” to resolve the matter on the earliest, it mentioned.

“Pfizer locations the utmost emphasis on affected person security and product high quality at each step within the manufacturing and provide chain course of. Out of an abundance of warning, and following a request by our native contract producer, Pfizer has at present positioned a voluntary cease on additional sale and use of its merchandise Magnex, Magnamycin and Zosyn in India on account of sure technical points dropped at our consideration by the contract manufacturing website in India. The matter is being investigated by the producer and Pfizer will take any additional actions in that case required,” the corporate informed ET.

  • Revealed On Could 18, 2023 at 06:50 PM IST

Be a part of the neighborhood of 2M+ trade professionals

Subscribe to our e-newsletter to get newest insights & evaluation.

Obtain ETHealthworld App

  • Get Realtime updates
  • Save your favorite articles


Scan to obtain App




Supply hyperlink

LEAVE A REPLY

Please enter your comment!
Please enter your name here